International Journal of Medical Investigation
Int J Med Invest
Medical Sciences
http://intjmi.com
1
admin
2322-2913
2345-640x
no
no
14
8888
13
en
jalali
1401
4
1
gregorian
2022
7
1
11
2
online
1
fulltext
en
Effect of Glibenclamide as a KATP Channel Blockade in Treatment of Parkinson Disease in the 6-Hydroxydopamine-Induced Animal Model
عمومى
General
پژوهشي
Research
Abstract: Parkinson disease is a most common neurodegerative disease in the world after Alzheimer disease. The most important cause of Parkinson's is damage to dopaminergic cells in the midbrain area. Glibenclamide is a second-generation sulfonylurea; it has an inhibitory effect on surface and mitochondrial KATP channels.Many reports indicate that glibenclamide can have neuroprotective effects in many neurodegenerative disorders. In the present study, we investigated the effect of glibenclamide pretreatment on behavioral symptom in 6-hydroxydopamine-induced animal model. Rats were divided into 4 groups (n=8 per group). Group (I): control without intervention Group (II): Vehicle, Group (III): received as pretreatment glibenclamide (3 mg/kg) i.p from begining of surgery until 4 weeks every day. Group (IV): received as pretreatment glibenclamide (8 mg/kg). In all group except healthy group received 6-OHDA by stereotaxic surgery. Development and severity of Parkinson disease were evaluated by apomorphine-induced rotational and rotarod behavioral tests. Our result showed that in two behavioral tests , pretreatment with glibenclamide could attenuate severity of Parkinson disease in treatment groups. There was no significant difference between treatment groups with different doses of glibenclamide. So our data showed pretreatment with KATP channel blockers reduces the severity of Parkinson's symptoms caused by the OHDA-6 model in rats in behavioral studies. <br>
93
100
http://intjmi.com/browse.php?a_code=A-10-1-440&slc_lang=en&sid=1
Shima
Mehrabadi
10031947532846005023
10031947532846005023
Yes
Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Azam
Alinaghipour
10031947532846005024
10031947532846005024
No
Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran